Thirty-day outcomes in patients at intermediate risk for surgery from the SAPIEN 3 European approval trial

2016 ◽  
Vol 12 (2) ◽  
pp. e235-e243 ◽  
Author(s):  
Alec Vahanian ◽  
Marina Urena ◽  
Thomas Walther ◽  
Hendrik Treede ◽  
Olaf Wendler ◽  
...  
Keyword(s):  
Intermediate Risk ◽  
Sapien 3 ◽  
European Approval

scholarly journals P753Long-term survival of low- and intermediate risk TAVI-patients: a real world, single center comparison of 684 patients treated with the sapien 3 or the sapien XT device

2017 ◽  
Vol 38 (suppl_1) ◽  
Author(s):  
J. Vendrik ◽  
M. Van Mourik ◽  
F. Van Kesteren ◽  
E.M.A. Wiegerinck ◽  
K.T. Koch ◽  
...  
Keyword(s):  
Real World ◽  
Intermediate Risk ◽  
Single Center ◽  
Term Survival ◽  
Sapien 3

scholarly journals TCT-674 Sex Specific Outcomes of TAVR with the Sapien 3 Valve: Insights From The PARTNER 2 S3 High-Risk and Intermediate-Risk Cohorts

2016 ◽  
Vol 68 (18) ◽  
pp. B272-B273 ◽  
Author(s):  
Molly Szerlip ◽  
Sarah Gualano ◽  
John Squiers ◽  
Jonathon White ◽  
Darshan Doshi ◽  
...  
Keyword(s):  
High Risk ◽  
Intermediate Risk ◽  
Sapien 3

scholarly journals Cost-effectiveness analysis of the SAPIEN 3 TAVI valve compared with surgery in intermediate-risk patients

2019 ◽  
Vol 22 (4) ◽  
pp. 289-296 ◽  
Author(s):  
Gordon Goodall ◽  
Mark Lamotte ◽  
Mafalda Ramos ◽  
Franck Maunoury ◽  
Barbora Pejchalova ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Cost Effectiveness Analysis ◽  
Intermediate Risk ◽  
Effectiveness Analysis ◽  
Risk Patients ◽  
Sapien 3

scholarly journals PARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients

2017 ◽  
Vol 2016 (4) ◽  
Author(s):  
Ahmed ElGuindy
Keyword(s):  
Lower Risk ◽  
Intermediate Risk ◽  
Surgical Risk ◽  
Transcatheter Aortic Valve ◽  
Risk Patients ◽  
Aortic Valve Implantation ◽  
Sapien 3 ◽  
Transcatheter Valve ◽  
Valve Implantation ◽  
Device Technology

Transcatheter aortic valve implantation (TAVI) is currently indicated for patients with severe symptomatic aortic stenosis who are unfit for surgery or when the surgical risk is high. Thanks to the increasing experience of surgeons, better patient selection, and substantial improvements in device technology, the procedure is now being performed with excellent outcomes and a progressively lower rate of complications. As a result, the cut-off threshold to implant a transcatheter valve is gradually moving toward lower risk patients. However, this is not supported by strong evidence from rigorous large clinical trials. The PARTNER 2A and SAPIEN 3 trials were conducted to address this gap in our knowledge. 

Sign in / Sign up

Export Citation Format

Share Document